We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Production of High-Quality Antibodies Continues 5-7 Months After SARS-CoV-2 Infection, Finds New Study

By HospiMedica International staff writers
Posted on 14 Oct 2020
Print article
Image: Production of High-Quality Antibodies Continues 5-7 Months after SARS-CoV-2 Infection, Finds New Study (Photo courtesy of University of Arizona Health Sciences)
Image: Production of High-Quality Antibodies Continues 5-7 Months after SARS-CoV-2 Infection, Finds New Study (Photo courtesy of University of Arizona Health Sciences)
A study of the production of antibodies from a sample of nearly 6,000 people who recovered from COVID-19 has revealed that immunity persists for at least several months after being infected with SARS-CoV-2.

One of the most significant questions about the novel coronavirus is whether people who are infected are immune from reinfection and, if so, for how long. When a virus first infects cells, the immune system deploys short-lived plasma cells that produce antibodies to immediately fight the virus. Those antibodies appear in blood tests within 14 days of infection. The second stage of the immune response is the creation of long-lived plasma cells, which produce high-quality antibodies that provide lasting immunity.

Researchers from the University of Arizona Health Sciences (Tucson, AZ, USA) tracked antibody levels over several months in people who tested positive for SARS-CoV-2 antibodies. The team also developed a blood test to check for SARS-CoV-2 antibodies by employing two different parts of the SARS-CoV-2 virus - S1 and S2. Most tests look for antibodies at S1, which includes the receptor-binding domain wherein the spike protein binds to a protein receptor to infect cells. The UArizona Health Sciences test also analyzes the S2 region of the spike protein. Antibodies must be present in both locations for the test to be determined positive.

For the study, 5,882 volunteers underwent antibody testing using the UArizona Health Sciences test. The researchers found SARS-CoV-2 antibodies are present in blood tests at viable levels for at least five to seven months, although they believe immunity lasts much longer. Earlier studies had extrapolated antibody production from initial infections and suggested antibody levels drop quickly after infection, providing only short-term immunity. The UArizona Health Sciences researchers believe that those conclusions focused on short-lived plasma cells and failed to take into account long-lived plasma cells and the high-affinity antibodies they produce.

“We clearly see high-quality antibodies still being produced five to seven months after SARS-CoV-2 infection,” said Deepta Bhattacharya, PhD, associate professor, UArizona College of Medicine – Tucson, Department of Immunobiology. “Many concerns have been expressed about immunity against COVID-19 not lasting. We used this study to investigate that question and found immunity is stable for at least five months.”

“Whether antibodies provide lasting protection against SARS-CoV-2 has been one of the most difficult questions to answer,” said UArizona Health Sciences Senior Vice President Michael D. Dake, MD, who is a co-author on the paper. “This research not only has given us the ability to accurately test for antibodies against COVID-19, but also has armed us with the knowledge that lasting immunity is a reality.”

Related Links:
University of Arizona Health Sciences

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Ultra Low Floor Level Bed
Solite Pro

Print article

Channels

Surgical Techniques

view channel
Image: The device\'s LEDs light up in several colors, allowing surgeons to see which areas they need to operate on (Photo courtesy of UC San Diego)

Flexible Microdisplay Visualizes Brain Activity in Real-Time To Guide Neurosurgeons

During brain surgery, neurosurgeons need to identify and preserve regions responsible for critical functions while removing harmful tissue. Traditionally, neurosurgeons rely on a team of electrophysiologists,... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more